Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently
needed on a global basis because treatment failure is an increasing problem. Drug …
needed on a global basis because treatment failure is an increasing problem. Drug …
Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives
F Alves, G Bilbe, S Blesson, V Goyal… - Clinical microbiology …, 2018 - Am Soc Microbiol
Research in visceral leishmaniasis in the last decade has been focused on how better to
use the existing medicines as monotherapy or in combination. Systematic research by …
use the existing medicines as monotherapy or in combination. Systematic research by …
Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical …
It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …
variation among patients. They are not intended to supplant physician judgment with respect …
An update on pharmacotherapy for leishmaniasis
Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …
Chemotherapy of leishmaniasis: present challenges
Cutaneous and visceral leishmaniasis are amongst the most devastating infectious diseases
of our time, affecting millions of people worldwide. The treatment of these serious diseases …
of our time, affecting millions of people worldwide. The treatment of these serious diseases …
Current and emerging medications for the treatment of leishmaniasis
Introduction: Leishmaniasis is a vector-borne neglected tropical disease which manifests as
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous …
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous …
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition
S Wyllie, S Brand, M Thomas… - Proceedings of the …, 2019 - National Acad Sciences
Visceral leishmaniasis (VL), caused by the protozoan parasites Leishmania donovani and
Leishmania infantum, is one of the major parasitic diseases worldwide. There is an urgent …
Leishmania infantum, is one of the major parasitic diseases worldwide. There is an urgent …
Why miltefosine—a life-saving drug for leishmaniasis—is unavailable to people who need it the most
Miltefosine, the only oral drug approved for the treatment of leishmaniasis—a parasitic
disease transmitted by sandflies—is considered as a success story of research and …
disease transmitted by sandflies—is considered as a success story of research and …
Leishmaniasis revisited: current aspects on epidemiology, diagnosis and treatment
SP Georgiadou, KP Makaritsis… - Journal of Translational …, 2015 - degruyter.com
Leishmaniasis is a vector-borne disease caused by protozoan parasites of the genus
Leishmania. It is transmitted by phlebotomine female sand flies of the genera Phlebotomus …
Leishmania. It is transmitted by phlebotomine female sand flies of the genera Phlebotomus …
An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis
S Palić, JH Beijnen, TPC Dorlo - International Journal of Antimicrobial …, 2022 - Elsevier
Miltefosine is an alkylphosphocholine agent with a broad spectrum of antiparasitic
properties. For over two decades, miltefosine has remained the only oral drug licensed and …
properties. For over two decades, miltefosine has remained the only oral drug licensed and …